Clinical Trial Search

Primary: Minutes of Moderate to Vigorous Physical Activity (MVPA) Per Day — 13.8; 17.9; 15.6; 21.8 min of MVPA/day

Primary: Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ — 103; 38 unitless

Primary: Number of Participants With Self-reported Past 7-day Smoking Abstinence — 12; 10; 12; 15 Participants

Primary: Maximum-tolerated Dose (MTD) of Inotuzumab Without DLT — 4; 2; 20 Participants

Primary: Number of Participants Achieving a BILAG-2004 Index-based Combined Lupus Assessment (BICLA) Response and an OGC Dose ≤ 7.5 mg/Day and ≤ Baseline Dose of Prednisone or…

Primary: Progression Free Survival (PFS) by BICR — 3.52; 1.92; 3.68; 3.22 Months

Primary: Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator — 21.0; 19.5; 25.5; 33.3 Percentage of Participants

Primary: 17-Item Hamilton Depression Rating Scale Responders — 0; 0; 1; 0 Participants

Primary: Fidelity to SNaP Intervention Procedures — 114.1; 151.4 score on a scale

Primary: To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo — 19.4; 33.3; 56.4; 56.4 Percentage — p=0.0025

Primary: Change in Cognitive/Memory Ability — 23.75 score on a scale

Primary: Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6 — 24.24 percent change

Primary: Radiograph Assessment of Progressive Tibial Radiolucencies — 110; 4; 3 Knees

Primary: Rate of Complete Tumor Necrosis — 4 Participants

Primary: Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1 — -66.11; -32.81 Percent Change